Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease and dyskinesias associated with the treatment of Parkinson's disease, Alzheimer's disease, and Multiple Sclerosis, as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease. Each of Neuraltus' clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company's target disease indications. Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Ari Azhir, PhD, Neuraltus' Chief Operating Officer; Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; and Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine. In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners

Patents 59show all

  • 29
    A61K - Preparations for medical, dental, or toilet purposes
  • 17
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 13
    C01B - Non-metallic elements
  • 10
    C07K - Peptides
  • 10
    Y02A - Technologies for adaptation to climate change
  • 3
    C07D - Heterocyclic compounds
  • 1
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 1
    C12N - Microorganisms or enzymes
  • 1
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms

Clinical Trials 5show all

2Phase 12Phase 21Phase 1/Phase 2

SEC Filings show all


3
D

Contact Information

2483 E. Bayshore Road Suite 212
Palo Alto, CA 94303
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$54,165,00611-502016-05-24Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2012-01-31$9,600,000Series BVantagePoint Capital Partners, Latterell Venture Partners, Adams Street Partners
2016-05-24$14,938,357Series UnknownVantagePoint Capital Partners, Latterell Venture Partners
2012-04-01$1,501,000Series UnknownAdams Street Partners, Latterell Venture Partners
2011-12-15$11,125,649Series A
2009-03-26$17,000,000Series AVantagePoint Capital Partners, Adams Street Partners, Latterell Venture Partners

SEC Form D Funding Events

DateOfferedSoldType
2012-05-31$11,125,649$11,125,649Equity, Option to Acquire, Other
2009-04-07$18,000,000$4,893,853Equity, Security to be Acquired, Other

Key Executives

  • Ari Azhir
    Executive Officer, Director
  • James N. Woody
    Director
  • Annette Bianchi
    Director
  • Terry Gould
    Director
  • Andrew Gengos
    Executive Officer, Director
  • James Woody
    Director
  • John Walker
    Director